论文部分内容阅读
目的：研究脂蛋白（a）[Lp（a）]与老年动脉硬化性疾病的关系，并探讨LP（a）是否通过抑制纤溶系统起作用。方法：对157例老年患者及健康志愿者进行了Lp（a）及部分凝血和纤溶因子的测定，按年龄及疾病情况分为5组。结果：Lp（a）水平在冠心病及脑血检组明显升高，分别为（364±378）mg／L及（34±180）mg／L，明显高于高血压组和健康对照组，各组部分凝血及纤溶因子水平差别无显著性。Lp（a）水平与性别、年龄、体重指数、吸烟与否、血脂指标、凝血及纤溶因子间无相关性。结论：Lp（a）升高是冠心病及脑血栓的一个独立的危险因素，推测Lp（a）并非主要通过抑制纤溶系统起作用，或者对纤溶的作用具有某些时相性。
AIM: To investigate the relationship between lipoprotein (a) [Lp (a)] and senile arteriosclerotic disease and to explore whether LP (a) acts by inhibiting fibrinolytic system. Methods: Lp (a) and partial coagulation and fibrinolysis were measured in 157 elderly patients and healthy volunteers. The patients were divided into five groups according to their age and disease status. Results: The levels of Lp (a) were significantly higher in patients with coronary heart disease and cerebral blood test (364 ± 378 mg / L and 34 ± 180 mg / L, respectively, which were significantly higher than those in hypertension group and healthy control group, There was no significant difference in the level of coagulation and fibrinolysis in each group. There was no correlation between Lp (a) level and gender, age, body mass index, smoking, blood lipid, coagulation and fibrinolysis. CONCLUSION: Elevated Lp (a) is an independent risk factor for coronary heart disease and cerebral thrombosis. It is speculated that Lp (a) does not act mainly through inhibition of the fibrinolytic system or has some phase behavior on fibrinolysis.